ArticleScience advances2021
MYO10 drives genomic instability and inflammation in cancer.
Article in Science advances, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 33 citations in OpenAlex.
- Emerging Roles of Cytoneme-Mediated Signaling in Cancer.International journal of molecular sciences · 2026Review
- MicNet: integrating spatially resolved transcriptomes and pathology images by contrastive deep neural network.Genome biology · 2026Article
- The E3 ligase β-TRCP1 earmarks OTUD3 for destruction to fine-tune cGAS activation.The Journal of biological chemistry · 2026Article
- Cancer and aging: complex associations and therapeutic targets.Molecular biomedicine · 2026Review
- Ubiquitin-conjugating Enzymes in Cancer.International journal of biological sciences · 2026Review
- Identification of Neurotrophic Factor Related Biomarkers and Mechanistic Insights into Neuropathic Pain via Integrated Bioinformatics Analysis.ACS omega · 2025Article
- Quantifying Intracellular Distributions of HaloTag-Labeled Proteins With SDS-PAGE and Epifluorescence Microscopy.Bio-protocol · 2025Article
- Long non-coding RNA TMEM51-AS1 inhibits colorectal cancer progression.Discover oncology · 2025Article
- Two cancer cell lines utilize Myosin 10 and the kinesin HSET differentially to maintain mitotic spindle bipolarity.PloS one · 2025Article
- Cells stably expressing shRNA against MYO10 display altered cell motility.microPublication biology · 2025Article
- Hundreds of myosin 10s are pushed to the tips of filopodia and could cause traffic jams on actin.eLife · 2024Article
- Hundreds of myosin 10s are pushed to the tips of filopodia and could cause traffic jams on actin.bioRxiv : the preprint server for biology · 2024Article
- Mechanisms underlying Myosin 10's contribution to the maintenance of mitotic spindle bipolarity.Molecular biology of the cell · 2024Article
- Esophageal Cancer with Early Onset in a Patient with Cri du Chat Syndrome.Diseases (Basel, Switzerland) · 2023Article
- Whole-exome sequencing of rectal neuroendocrine tumors.Endocrine-related cancer · 2023Article
- A novel sorbicillinoid compound as a potent anti-inflammation agent through inducing NLRP3 protein degradation.British journal of pharmacology · 2023Article
- MYO10 regulates genome stability and cancer inflammation through mediating mitosis.Cell reports · 2023Article
- Autophagy modulators influence the content of important signalling molecules in PS-positive extracellular vesicles.Cell communication and signaling : CCS · 2023Article
- cGAS-STING signalling in cancer: striking a balance with chromosomal instability.Biochemical Society transactions · 2023Review
- DNA damage repair kinase DNA-PK and cGAS synergize to induce cancer-related inflammation in glioblastoma.The EMBO journal · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
Abstract
Genomic instability is a hallmark of human cancer; yet the underlying mechanisms remain poorly understood. Here, we report that the cytoplasmic unconventional Myosin X (MYO10) regulates genome stability, through which it mediates inflammation in cancer. MYO10 is an unstable protein that undergoes ubiquitin-conjugating enzyme H7 (UbcH7)/β-transducin repeat containing protein 1 (β-TrCP1)–dependent degradation. MYO10 is upregulated in both human and mouse tumors and its expression level predisposes tumor progression and response to immune therapy. Overexpressing MYO10 increased genomic instability, elevated the cyclic GMP-AMP synthase (cGAS)/stimulator of interferon genes (STING)–dependent inflammatory response, and accelerated tumor growth in mice. Conversely, depletion of MYO10 ameliorated genomic instability and reduced the inflammation signaling. Further, inhibiting inflammation or disrupting
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.